106.87 USD
+0.95 (+0.9%)
106.91 USD
+0.04 (+0.04%)
Taking everything into account, INCY scores 6 out of 10 in our fundamental rating. INCY was compared to 530 industry peers in the Biotechnology industry. INCY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. INCY may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make INCY a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
In the past year INCY was profitable.
INCY had a positive operating cash flow in the past year.
Of the past 5 years INCY 4 years were profitable.
Of the past 5 years INCY 4 years had a positive operating cash flow.
1.2 Ratios
INCY has a better Return On Assets (18.78%) than 96.79% of its industry peers.
With an excellent Return On Equity value of 25.55%, INCY belongs to the best of the industry, outperforming 96.98% of the companies in the same industry.
INCY has a Return On Invested Capital of 19.88%. This is amongst the best in the industry. INCY outperforms 97.74% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for INCY is significantly below the industry average of 18.28%.
The 3 year average ROIC (7.24%) for INCY is below the current ROIC(19.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROIC | 19.88% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 24.69%, INCY belongs to the best of the industry, outperforming 94.72% of the companies in the same industry.
In the last couple of years the Profit Margin of INCY has declined.
The Operating Margin of INCY (26.10%) is better than 95.85% of its industry peers.
In the last couple of years the Operating Margin of INCY has declined.
INCY has a Gross Margin of 93.47%. This is amongst the best in the industry. INCY outperforms 94.53% of its industry peers.
In the last couple of years the Gross Margin of INCY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% |
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
2. Health
2.1 Basic Checks
INCY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for INCY has been reduced compared to 1 year ago.
INCY has less shares outstanding than it did 5 years ago.
INCY has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 9.38 indicates that INCY is not in any danger for bankruptcy at the moment.
The Altman-Z score of INCY (9.38) is better than 81.70% of its industry peers.
INCY has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
INCY's Debt to FCF ratio of 0.03 is amongst the best of the industry. INCY outperforms 96.42% of its industry peers.
INCY has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of INCY (0.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 9.38 |
ROIC/WACC2.25
WACC8.82%
2.3 Liquidity
A Current Ratio of 3.20 indicates that INCY has no problem at all paying its short term obligations.
INCY has a Current ratio of 3.20. This is in the lower half of the industry: INCY underperforms 61.89% of its industry peers.
INCY has a Quick Ratio of 3.13. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.13, INCY is doing worse than 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 |
3. Growth
3.1 Past
INCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 575.79%, which is quite impressive.
The earnings per share for INCY have been decreasing by -14.21% on average. This is quite bad
INCY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.09%.
Measured over the past years, INCY shows a quite strong growth in Revenue. The Revenue has been growing by 14.46% on average per year.
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
3.2 Future
The Earnings Per Share is expected to grow by 28.45% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 1.17% on average over the next years.
EPS Next Y428.71%
EPS Next 2Y146.91%
EPS Next 3Y91%
EPS Next 5Y28.45%
Revenue Next Year18.26%
Revenue Next 2Y14.47%
Revenue Next 3Y12.87%
Revenue Next 5Y1.17%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.65 indicates a correct valuation of INCY.
95.47% of the companies in the same industry are more expensive than INCY, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.19. INCY is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 13.28, the valuation of INCY can be described as correct.
Based on the Price/Forward Earnings ratio, INCY is valued cheaper than 96.98% of the companies in the same industry.
INCY's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.65 | ||
| Fwd PE | 13.28 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of INCY indicates a rather cheap valuation: INCY is cheaper than 95.66% of the companies listed in the same industry.
INCY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. INCY is cheaper than 96.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.53 | ||
| EV/EBITDA | 12.92 |
4.3 Compensation for Growth
INCY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of INCY may justify a higher PE ratio.
A more expensive valuation may be justified as INCY's earnings are expected to grow with 91.00% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y146.91%
EPS Next 3Y91%
5. Dividend
5.1 Amount
No dividends for INCY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
106.87
+0.95 (+0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.27%
Inst Owner Change0%
Ins Owners0.96%
Ins Owner Change-8.35%
Market Cap20.98B
Revenue(TTM)4.81B
Net Income(TTM)1.19B
Analysts75
Price Target101.7 (-4.84%)
Short Float %5.6%
Short Ratio4.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.23%
Min EPS beat(2)4.72%
Max EPS beat(2)33.74%
EPS beat(4)3
Avg EPS beat(4)10.09%
Min EPS beat(4)-10.01%
Max EPS beat(4)33.74%
EPS beat(8)3
Avg EPS beat(8)-1.54%
EPS beat(12)6
Avg EPS beat(12)-3.05%
EPS beat(16)7
Avg EPS beat(16)-8.28%
Revenue beat(2)2
Avg Revenue beat(2)5.08%
Min Revenue beat(2)3.45%
Max Revenue beat(2)6.72%
Revenue beat(4)4
Avg Revenue beat(4)3.8%
Min Revenue beat(4)1.09%
Max Revenue beat(4)6.72%
Revenue beat(8)5
Avg Revenue beat(8)1.4%
Revenue beat(12)7
Avg Revenue beat(12)0.24%
Revenue beat(16)9
Avg Revenue beat(16)0.48%
PT rev (1m)7.59%
PT rev (3m)18.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.9%
EPS NY rev (1m)0%
EPS NY rev (3m)10.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.65 | ||
| Fwd PE | 13.28 | ||
| P/S | 4.36 | ||
| P/FCF | 17.53 | ||
| P/OCF | 16.77 | ||
| P/B | 4.51 | ||
| P/tB | 4.79 | ||
| EV/EBITDA | 12.92 |
EPS(TTM)6.42
EY6.01%
EPS(NY)8.05
Fwd EY7.53%
FCF(TTM)6.1
FCFY5.71%
OCF(TTM)6.37
OCFY5.96%
SpS24.52
BVpS23.69
TBVpS22.29
PEG (NY)0.04
PEG (5Y)N/A
Graham Number58.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROCE | 25.17% | ||
| ROIC | 19.88% | ||
| ROICexc | 48.14% | ||
| ROICexgc | 55.55% | ||
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% | ||
| FCFM | 24.87% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
ROICexc(3y)25.32%
ROICexc(5y)N/A
ROICexgc(3y)31.6%
ROICexgc(5y)N/A
ROCE(3y)9.17%
ROCE(5y)N/A
ROICexgc growth 3Y-34.92%
ROICexgc growth 5Y-33.44%
ROICexc growth 3Y-36.33%
ROICexc growth 5Y-29.08%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
F-Score7
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 59.08% | ||
| Cap/Sales | 1.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 92.81% | ||
| Profit Quality | 100.71% | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 | ||
| Altman-Z | 9.38 |
F-Score7
WACC8.82%
ROIC/WACC2.25
Cap/Depr(3y)83.51%
Cap/Depr(5y)185.09%
Cap/Sales(3y)1.73%
Cap/Sales(5y)3.66%
Profit Quality(3y)367.72%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
EPS Next Y428.71%
EPS Next 2Y146.91%
EPS Next 3Y91%
EPS Next 5Y28.45%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
Revenue Next Year18.26%
Revenue Next 2Y14.47%
Revenue Next 3Y12.87%
Revenue Next 5Y1.17%
EBIT growth 1Y6374.01%
EBIT growth 3Y-44.05%
EBIT growth 5Y-23.34%
EBIT Next Year366.76%
EBIT Next 3Y85.61%
EBIT Next 5Y26.81%
FCF growth 1Y106.03%
FCF growth 3Y-24.05%
FCF growth 5Y-17.01%
OCF growth 1Y97.88%
OCF growth 3Y-23.52%
OCF growth 5Y-13.95%
INCYTE CORP / INCY FAQ
What is the fundamental rating for INCY stock?
ChartMill assigns a fundamental rating of 6 / 10 to INCY.
What is the valuation status of INCYTE CORP (INCY) stock?
ChartMill assigns a valuation rating of 8 / 10 to INCYTE CORP (INCY). This can be considered as Undervalued.
How profitable is INCYTE CORP (INCY) stock?
INCYTE CORP (INCY) has a profitability rating of 7 / 10.
How financially healthy is INCYTE CORP?
The financial health rating of INCYTE CORP (INCY) is 7 / 10.
Can you provide the expected EPS growth for INCY stock?
The Earnings per Share (EPS) of INCYTE CORP (INCY) is expected to grow by 428.71% in the next year.